Patent applications published 16 February 2011

Published: 1-Apr-2011
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • Benzene sulphonamide thiazole and oxazole compounds
    GlaxoSmithKline 2282636*

  • Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
    Schapira, Jay N; Makkar, Raj 2282718*

  • Compsns and methods for treating multiple sclerosis
    Revalesio 2282719*

  • Intracellular antibody delivery
    Biocompatibles UK 2282720*

  • Transnasal anticonvulsive pharmaceutical compsn comprising poorly soluble anticonvulsant
    SK Holdings 2282721*

  • Self-microemulsifying systems incorporated into liquid core microcapsules
    LEK Pharmaceuticals 2282722*

  • Endoplasmic reticulum targeting liposomes
    University of Oxford 2282723*

  • Modified drugs for use in liposomal nanoparticles
    The University of British Columbia 2282724*

  • Nasal formulations of insulin
    CPEX Pharmaceuticals 2282725*

  • Delivery system for an active ingredient
    Firmenich 2282726*

  • Polymerised micelles
    Les Laboratoires Servier; Commissariat a l ‘energie Atomique 2282727*

  • Modulators of the VPS10P-domain receptors for the treatment of cardiovascular disease
    H Lundbeck 2282728*

  • Methods and compsns for treating inflammation and inflammation-related pathologies
    Livionex 2282729*

  • Methods of treating fungal infections
    Northeastern University 2282730*

  • Combination therapy for acne vulgaris comprising adapalene 0.3% gel with clindamycin/benzoyl peroxide gel
    Galderma Research & Development 2282731*

  • Use of an olive oil extract to control skin ageing
    Sprim 2282732*

  • Protection of normal cells
    Florida Atlantic University; The Hospital for Special Surgery 2282733*

  • Method for protecting humans against superficial vasodilator flush syndrome
    Theta Biological Consulting & Development 2282734*

  • Compounds, compsns and methods of or making the same
    Signum Biosciences 2282735*

  • Tetrazole compounds for reducing citric acid
    Wellstat Therapeutics 2282736*

  • Compsns and methods for treating periodontal disease comprising clonidine, sulindac and/or fluoxinolone
    Warsaw Orthopaedic 2282737*

  • Promoting axon regeneration in the adult CNS through control of protein translation
    Children’s Medical Center Corp 2282738*

  • Sequential administration of chemo-therapeutic agents for treatment of cancer
    Schering 2282739*

  • Antifolate compsns
    Chelsea Therapeutics 2282740*

  • Treating eosinophilic esophagitis
    Meritage Pharma 2282741*

  • Inhibitors of fatty acid amide hydrolase
    Infinity Pharmaceuticals 2282742*

  • Sulphated unsaturated disaccharide chondroitin sulphate in connective tissue protection and repair
    Nestec 2282743*

  • Oligomeric compounds comprising tricyclic nucleosides and methods for their use
    Isis Pharmaceuticals 2282744*

  • Composite enterocystoplasty
    Advanced Technologies and Regenerative Medicine 2282745*

  • Compsns and methods using stem cells in cutaneous wound healing
    Neostem 2282746*

  • Use of enteric glia
    Neurological Technologies 2282747*

  • Treatment of brain damage using umbilical cord blood cells
    Stemcyte 2282748*

  • Anti-adhesion barrier wound dressing comprising processed amniotic tissue and method of use
    Allosource 2282749*

  • Extract with high amount of bioactive compounds and its use
    Aromtech 2282750*

  • Compartment-specific plant extract combination of Gingko biloba extract and ginseng extract having a tandem effect
    Merz Pharma 2282751*

  • Saponin extract from Saponaria spp and uses thereof
    National Research Council of Canada; University of Saskatchewan 2282752*

  • Assay for pathogenic conformers
    Novartis 2282753*

  • Method of treating peripheral arterial disease
    Orthologic; Texas A&M University System 2282754*

  • Inhibition of angiogenesis
    Transmolecular 2282755*

  • Methods of diagnosing, preventing and treating bone mass diseases
    The Trustees of Columbia University in the City of New York 2282756*

  • Neutralisation of GM-CSF for the treatment of heart failure
    Kalobios Pharmaceuticals 2282757*

  • Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
    BioArtic Neuroscience 2282758*

  • Use of nucleic acids with reduced pressure therapy for treating wounds
    KCI Licensing 2282759*

  • Method for the treatment or prophylaxis of chronic inflammatory diseases
    Drug Discovery Factory 2282760*

  • Inhibition of scarring using TGF-beta 3
    Renovo 2282761*

  • Novel macrocyclic inhibitors of hepatitis C virus replication
    Intermune 2282762*

  • Compsns useful in the treatment of diabetes and other chronic disorders
    National Institute of Immunology; Indian Institute of Science 2282763*

See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now